Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corcept Therapeutics has initiated Phase III trial with Corlux, a cortisol receptor antagonist, for the treatment of endogenous Cushing's syndrome.
Subscribe to our email newsletter
In September, the company reported that the FDA had opened the investigational new drug application (IND) for Corlux for the treatment of endogenous Cushing’s syndrome, which allowed it to initiate this 50-patient open label study. In the communication regarding the opening of the IND, the FDA indicated that a single study may provide a reasonable basis for the submission of a new drug application for the treatment of endogenous Cushing’s syndrome.